Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. uri icon

Overview

publication date

  • December 15, 2016

Research

keywords

  • Alkylating Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Follicular
  • Purines
  • Quinazolinones
  • Rituximab

Identity

PubMed Central ID

  • PMC5395130

Scopus Document Identifier

  • 85016993064

Digital Object Identifier (DOI)

  • 10.3324/haematol.2016.151738

PubMed ID

  • 27979923

Additional Document Info

volume

  • 102

issue

  • 4